

**LUPUS ACADEMY CHINA 2022**  
**OPTIMIZING OUTCOMES AND PREVENTING DAMAGE IN SLE AND LUPUS NEPHRITIS**

**Meeting Chair: Sandra Navarra (Philippines)**  
**27th February 2022: CST (UTC+8 Beijing) 15:00–18:55 hours**

**Session 1: SLE TREATMENT**

<i>Moderators: Sandra Navarra (Philippines) &amp; Nan Shen (Shanghai, China)</i>		
<b>15:00</b>	SLE Treatment Challenges in China: A Case Based Review <i>Q&amp;A and Discussion (15 Mins)</i>	<i>Nan Shen (Shanghai, China)</i>
<b>15:30</b>	Targeting remission and low disease activity in SLE <i>Q&amp;A and Discussion (15 Mins)</i>	<i>Andrea Doria (Italy)</i>
<b>16:00</b>	Strategies for minimizing corticosteroid exposure in SLE <i>Q&amp;A and Discussion (15 Mins)</i>	<i>Zahir Amoura (France)</i>
<b>16:30</b>	Panel Discussion (15 Mins)	<i>All</i>

**Session 2: MANAGEMENT OF LUPUS NEPHRITIS**

<i>Moderators: Sandra Navarra (Philippines) &amp; Feng Yu (Beijing, China)</i>		
<b>16:45</b>	Lupus Nephritis Treatment Challenges in China: A Case Based Review <i>Q&amp;A and Discussion (15 Mins)</i>	<i>Feng Yu (Beijing, China)</i>
<b>17:15</b>	Debate: Management of Lupus Nephritis The matter of the debate (10 mins)	<i>Ronald van Vollenhoven (Netherlands)</i>
	All lupus nephritis patients should be initially managed with <b>both</b> established standard therapies <b>and</b> the new generation drugs (20 mins + 10 mins rebuttal)	<i>Onno Teng (Netherlands)</i>
	All lupus nephritis patients should be initially managed with established standard therapies <b>alone</b> (20 mins + 10 mins rebuttal)	<i>Dimitrios Boumpas (Greece)</i>
	<i>Q&amp;A and Discussion (30 Mins)</i>	<i>All</i>
<b>18:55</b>	Close	

**Learning Objectives**

- Illustrate case-based treatment challenges of SLE and lupus nephritis in China
- Explain best outcome measures for the optimal management of SLE
- Discuss best treatment strategies for preventing damage in SLE
- Demonstrate case-based treatment clinical practice challenges in lupus nephritis